Western New York BloodCare
Welcome,         Profile    Billing    Logout  
 18 Trials 
29 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Roberts, Jonathan
NCT02932618 / 2016-001477-33: A Study of Recombinant Von Willebrand Factor (rVWF) With or Without ADVATE in Children With Severe Von Willebrand Disease (VWD)

Recruiting
3
34
Europe, US, RoW
von Willebrand factor (Recombinant), VONVENDI, rVWF, BAX111, BAX 111, Antihemophilic Factor (Recombinant), ADVATE, Recombinant Factor VIII, rFVIII
Baxalta now part of Shire, Takeda Development Center Americas, Inc.
Von Willebrand Disease
01/25
01/25
AHAEmi, NCT05345197: Emicizumab in Patients With Acquired Hemophilia A

Recruiting
2
51
US
emicizumab, Hemlibra (R)
University of Washington, Genentech, Inc.
Acquired Hemophilia A
07/25
12/25
BCDI-XII, NCT05500807: Emicizumab for Severe Von Willebrand Disease (VWD) and VWD/Hemophilia A

Recruiting
1
40
US
Emicizumab, Hemlibra
Bleeding and Clotting Disorders Institute Peoria, Illinois, Genentech, Inc.
Von Willebrand Disease, Type 3, Concomitant VWD and Hemophilia
11/25
03/26
VIP, NCT04146376: Von Willebrand Factor in Pregnancy () Study

Recruiting
N/A
110
US
Use of a postpartum diary and additional blood draws, VWF replacement therapy with Wilate, Tranexamic acid, Use of a postpartum diary and additional blood draws.
University of Washington, Ergomed, Octapharma
Von Willebrand Diseases
12/26
12/26
NCT05966662: Shockwave C2+ 2Hz Coronary IVL Catheter in Calcified Coronary Arteries (Disrupt CAD DUO)

Active, not recruiting
N/A
145
US
IVL with Shockwave C2+ 2Hz Coronary IVL Catheter
Shockwave Medical, Inc.
Coronary Artery Disease, Myocardial Infarction
01/25
12/25
ACTIVIIITY, NCT06530030: Goal Attainment and Physical Activity in People With Hemophilia A

Recruiting
N/A
35
US
efanesoctocog alfa, Altuviiio
Sanofi
Hemophilia A
08/26
08/26
NCT05132361: SELUTION4SFA Trial

Recruiting
N/A
300
Europe, US, RoW
SELUTION SLR™ 018 DEB, Plain (Uncoated) Balloon Angioplasty (PTA)
MedAlliance, LLC, NAMSA, Cordis Corporation
Peripheral Arterial Disease, Superficial Femoral Artery Stenosis
08/25
12/29
NCT05960474: Coronary Microvascular Disease (CMD) Registry

Recruiting
N/A
1000
US
Outcomes for Patients with CMD
Medstar Health Research Institute
Coronary Microvascular Dysfunction
01/33
01/33
ATHN Transcends, NCT04398628: A Natural History Study of Non-Neoplastic Hematologic Disorders

Recruiting
N/A
3000
US
American Thrombosis and Hemostasis Network, Pfizer, Hemophilia of Georgia, Inc., Genentech, Inc., Hemab Therapeutics, CSL Behring, Sanofi, Novo Nordisk A/S
Hematologic Disorder, Bleeding Disorder, Connective Tissue Disorder, Hemophilia, Thrombosis, Von Willebrand Diseases, Thrombophilia, Rare Bleeding Disorder, Platelet Disorder, Factor IX Deficiency, Factor VIII Deficiency, Thalassemia, Sickle Cell Disease
06/35
12/35
Acosta, Michelle
NCT05248594: Real World Use of Emicizumab in Infants and Children Ages 0-3 Years With Hemophilia A

Recruiting
N/A
50
US
HEMLIBRA, Emicizumab-kxwh
Montefiore Medical Center, Genentech, Inc.
Hemophilia A
08/25
08/25
ATHN Transcends, NCT04398628: A Natural History Study of Non-Neoplastic Hematologic Disorders

Recruiting
N/A
3000
US
American Thrombosis and Hemostasis Network, Pfizer, Hemophilia of Georgia, Inc., Genentech, Inc., Hemab Therapeutics, CSL Behring, Sanofi, Novo Nordisk A/S
Hematologic Disorder, Bleeding Disorder, Connective Tissue Disorder, Hemophilia, Thrombosis, Von Willebrand Diseases, Thrombophilia, Rare Bleeding Disorder, Platelet Disorder, Factor IX Deficiency, Factor VIII Deficiency, Thalassemia, Sickle Cell Disease
06/35
12/35
Sidonio, Robert
The Atlanta Study, NCT04030052: Emicizumab PUPs and Nuwiq ITI Study

Withdrawn
3
2
US
Nuwiq (low dose protocol), Simoctocog alfa, HEMLIBRA, Emicizumab, ACE910, and RO5534262, Nuwiq (Atlanta protocol)
Emory University, Genentech, Inc.
Hemophilia A
01/23
01/23
NCT04563520: SAFE Study: Safety of aPCC Following Emicizumab Prophylaxis

Recruiting
3
20
US
aPCC-emicizumab, ACE910, Hemlibra and RO5534262, FEIBA, Anti-Inhibitor Coagulant Complex, rFVIIa
Emory University, Takeda Pharmaceuticals North America, Inc.
Hemophilia A
09/25
09/25
ATHN 9, NCT03853486: Severe VWD Natural History Study

Active, not recruiting
N/A
108
US
American Thrombosis and Hemostasis Network, Takeda
Von Willebrand Diseases
12/24
01/25
MOTIVATE, NCT04023019: Treatment of Hemophilia A Patients With FVIII Inhibitors

Recruiting
N/A
120
Europe, US
Nuwiq, Octanate, Wilate, Emicizumab, Hemlibra, Recombinant factor VIIa (rFVIIa), NovoSeven, Activated prothrombin complex concentrate (aPCC), FEIBA
Emory University, Octapharma
Hemophilia A
12/28
06/29
ATHN Transcends, NCT04398628: A Natural History Study of Non-Neoplastic Hematologic Disorders

Recruiting
N/A
3000
US
American Thrombosis and Hemostasis Network, Pfizer, Hemophilia of Georgia, Inc., Genentech, Inc., Hemab Therapeutics, CSL Behring, Sanofi, Novo Nordisk A/S
Hematologic Disorder, Bleeding Disorder, Connective Tissue Disorder, Hemophilia, Thrombosis, Von Willebrand Diseases, Thrombophilia, Rare Bleeding Disorder, Platelet Disorder, Factor IX Deficiency, Factor VIII Deficiency, Thalassemia, Sickle Cell Disease
06/35
12/35
Patel, Hinal
INC-6603, NCT01203085: Development of Charcot Marie Tooth Disease (CMT) Pediatric Scale for Children With CMT

Recruiting
N/A
500
Europe, US, RoW
University of Iowa, National Institute of Neurological Disorders and Stroke (NINDS), Muscular Dystrophy Association, University of Rochester, Children's Hospital of Philadelphia, University College London Hospitals, Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta, Sydney Children's Hospitals Network, Nemours Children's Clinic
Charcot Marie Tooth Disease
12/24
12/24
INC-6602, NCT01193088: Genetics of Charcot Marie Tooth (CMT) - Modifiers of CMT1A, New Causes of CMT2

Recruiting
N/A
1050
Europe, US, RoW
University of Iowa, National Institute of Neurological Disorders and Stroke (NINDS), Muscular Dystrophy Association, University of Rochester, University of Pennsylvania, King's College Hospital NHS Trust, Sydney Children's Hospitals Network, Children's Hospital of Philadelphia, University of Miami, Johns Hopkins University, Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta, Cedars-Sinai Medical Center, Nemours Children's Clinic, Stanford University, University of Minnesota, Massachusetts General Hospital, University of Colorado, Denver, Children's National Research Institute, University of Michigan, St. Jude Children's Research Hospital, Connecticut Children's Medical Center, Seattle Children's Hospital, The Hospital for Sick Children
Charcot-Marie-Tooth Disease, Type Ia (Disorder), HMSN
12/26
12/26
ATHN Transcends, NCT04398628: A Natural History Study of Non-Neoplastic Hematologic Disorders

Recruiting
N/A
3000
US
American Thrombosis and Hemostasis Network, Pfizer, Hemophilia of Georgia, Inc., Genentech, Inc., Hemab Therapeutics, CSL Behring, Sanofi, Novo Nordisk A/S
Hematologic Disorder, Bleeding Disorder, Connective Tissue Disorder, Hemophilia, Thrombosis, Von Willebrand Diseases, Thrombophilia, Rare Bleeding Disorder, Platelet Disorder, Factor IX Deficiency, Factor VIII Deficiency, Thalassemia, Sickle Cell Disease
06/35
12/35
Simpson, Mindy
The Atlanta Study, NCT04030052: Emicizumab PUPs and Nuwiq ITI Study

Withdrawn
3
2
US
Nuwiq (low dose protocol), Simoctocog alfa, HEMLIBRA, Emicizumab, ACE910, and RO5534262, Nuwiq (Atlanta protocol)
Emory University, Genentech, Inc.
Hemophilia A
01/23
01/23
HISTORY, NCT03797495 / 2012-004442-15: Study of Individuals Affected With Hypoplasminogenemia

Recruiting
N/A
100
Europe, Canada, US, RoW
Indiana Hemophilia &Thrombosis Center, Inc., Fondazione Angelo Bianchi Bonomi
Plasminogen Deficiency
03/27
04/27
ATHN Transcends, NCT04398628: A Natural History Study of Non-Neoplastic Hematologic Disorders

Recruiting
N/A
3000
US
American Thrombosis and Hemostasis Network, Pfizer, Hemophilia of Georgia, Inc., Genentech, Inc., Hemab Therapeutics, CSL Behring, Sanofi, Novo Nordisk A/S
Hematologic Disorder, Bleeding Disorder, Connective Tissue Disorder, Hemophilia, Thrombosis, Von Willebrand Diseases, Thrombophilia, Rare Bleeding Disorder, Platelet Disorder, Factor IX Deficiency, Factor VIII Deficiency, Thalassemia, Sickle Cell Disease
06/35
12/35
Eason, Ashley
ATHN 16, NCT04647227: SEVENFACT® for Bleeding Events in Hemophilia With Inhibitors

Recruiting
4
55
US
coagulation factor VIIa [recombinant]-jncw, SEVENFACT
American Thrombosis and Hemostasis Network, LFB USA, Inc.
Hemophilia A With Inhibitor, Hemophilia B With Inhibitor
09/26
03/27
ATHN Transcends, NCT04398628: A Natural History Study of Non-Neoplastic Hematologic Disorders

Recruiting
N/A
3000
US
American Thrombosis and Hemostasis Network, Pfizer, Hemophilia of Georgia, Inc., Genentech, Inc., Hemab Therapeutics, CSL Behring, Sanofi, Novo Nordisk A/S
Hematologic Disorder, Bleeding Disorder, Connective Tissue Disorder, Hemophilia, Thrombosis, Von Willebrand Diseases, Thrombophilia, Rare Bleeding Disorder, Platelet Disorder, Factor IX Deficiency, Factor VIII Deficiency, Thalassemia, Sickle Cell Disease
06/35
12/35
Kavinde, Rachana
ATHN Transcends, NCT04398628: A Natural History Study of Non-Neoplastic Hematologic Disorders

Recruiting
N/A
3000
US
American Thrombosis and Hemostasis Network, Pfizer, Hemophilia of Georgia, Inc., Genentech, Inc., Hemab Therapeutics, CSL Behring, Sanofi, Novo Nordisk A/S
Hematologic Disorder, Bleeding Disorder, Connective Tissue Disorder, Hemophilia, Thrombosis, Von Willebrand Diseases, Thrombophilia, Rare Bleeding Disorder, Platelet Disorder, Factor IX Deficiency, Factor VIII Deficiency, Thalassemia, Sickle Cell Disease
06/35
12/35
Schaefer, Beverly
ATHN Transcends, NCT04398628: A Natural History Study of Non-Neoplastic Hematologic Disorders

Recruiting
N/A
3000
US
American Thrombosis and Hemostasis Network, Pfizer, Hemophilia of Georgia, Inc., Genentech, Inc., Hemab Therapeutics, CSL Behring, Sanofi, Novo Nordisk A/S
Hematologic Disorder, Bleeding Disorder, Connective Tissue Disorder, Hemophilia, Thrombosis, Von Willebrand Diseases, Thrombophilia, Rare Bleeding Disorder, Platelet Disorder, Factor IX Deficiency, Factor VIII Deficiency, Thalassemia, Sickle Cell Disease
06/35
12/35
Barclay, Dominique
ATHN Transcends, NCT04398628: A Natural History Study of Non-Neoplastic Hematologic Disorders

Recruiting
N/A
3000
US
American Thrombosis and Hemostasis Network, Pfizer, Hemophilia of Georgia, Inc., Genentech, Inc., Hemab Therapeutics, CSL Behring, Sanofi, Novo Nordisk A/S
Hematologic Disorder, Bleeding Disorder, Connective Tissue Disorder, Hemophilia, Thrombosis, Von Willebrand Diseases, Thrombophilia, Rare Bleeding Disorder, Platelet Disorder, Factor IX Deficiency, Factor VIII Deficiency, Thalassemia, Sickle Cell Disease
06/35
12/35
Hagan, Rebekah
ATHN Transcends, NCT04398628: A Natural History Study of Non-Neoplastic Hematologic Disorders

Recruiting
N/A
3000
US
American Thrombosis and Hemostasis Network, Pfizer, Hemophilia of Georgia, Inc., Genentech, Inc., Hemab Therapeutics, CSL Behring, Sanofi, Novo Nordisk A/S
Hematologic Disorder, Bleeding Disorder, Connective Tissue Disorder, Hemophilia, Thrombosis, Von Willebrand Diseases, Thrombophilia, Rare Bleeding Disorder, Platelet Disorder, Factor IX Deficiency, Factor VIII Deficiency, Thalassemia, Sickle Cell Disease
06/35
12/35
Yarnall, James
ATHN Transcends, NCT04398628: A Natural History Study of Non-Neoplastic Hematologic Disorders

Recruiting
N/A
3000
US
American Thrombosis and Hemostasis Network, Pfizer, Hemophilia of Georgia, Inc., Genentech, Inc., Hemab Therapeutics, CSL Behring, Sanofi, Novo Nordisk A/S
Hematologic Disorder, Bleeding Disorder, Connective Tissue Disorder, Hemophilia, Thrombosis, Von Willebrand Diseases, Thrombophilia, Rare Bleeding Disorder, Platelet Disorder, Factor IX Deficiency, Factor VIII Deficiency, Thalassemia, Sickle Cell Disease
06/35
12/35

Download Options